Physician profile
Jordan Wagner
NPI 1558870881
$1,976.96
in general payments reported to CMS, 2019-2025
23 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.45 · 2022: $476 · 2023: $353 · 2024: $942 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $583.35 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $188.34 | 2022-2025 | Azstarys |
| Kaleo, INC. | $149.02 | 2022-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $118.16 | 2023-2025 | |
| Cranial Technologies, INC | $113.21 | 2022-2025 | Doc Band |
| Sobi, INC | $103.17 | 2021-2023 | |
| Tris Pharma INC | $98.33 | 2022 | |
| Ironshore Pharmaceuticals INC. | $72.64 | 2023-2024 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $69.72 | 2024 | Relexxii |
| Tempus Ai, INC | $67.46 | 2024 | |
| Seqirus USA INC | $59.20 | 2022-2024 | Flucelvax |
| Cognoa, INC. | $51.45 | 2021-2022 | |
| Pfizer INC. | $38.49 | 2021-2025 | |
| Sanofi Pasteur INC. | $37.82 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $33.71 | 2024-2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $29.54 | 2025 | |
| Merck Sharp & Dohme LLC | $28.51 | 2022-2023 | Vaxelis, Gardasil 9, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $27.41 | 2024 | Flumist Quadrivalent |
| Kyowa Kirin, INC. | $26.95 | 2023 | Crysvita |
| Meridian Bioscience INC. | $24.70 | 2024 | |
| Organon LLC | $20.01 | 2023 | Nexplanon |
| Ultragenyx Pharmaceutical INC. | $18.70 | 2022 | |
| Neurocrine Biosciences, INC. | $17.07 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.